These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Thinking more about therapy with convalescent plasma for COVID-19 patients. Han G; Zhou YH Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512 [No Abstract] [Full Text] [Related]
5. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627 [TBL] [Abstract][Full Text] [Related]
6. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light. Larrea L; Castro E; Navarro L; Vera B; Francés-Gómez C; Sánchez-Sendra B; Giménez Á; Castelló E; Collado M; Vayá MJ; Mirabet V; Callao V; Ortiz-de-Salazar MI; Roig R; Geller R; Arbona C Blood Transfus; 2022 May; 20(3):206-212. PubMed ID: 34369870 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants. Bellusci L; Golding H; Khurana S J Clin Invest; 2023 Apr; 133(8):. PubMed ID: 36821375 [No Abstract] [Full Text] [Related]
8. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study. Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958 [TBL] [Abstract][Full Text] [Related]
9. [COVID-19: Still a place for the convalescent plasma? Focus on the immunocompromised patients]. Richier Q; Hueso T; Tiberghien P; Lacombe K Rev Med Interne; 2023 Sep; 44(9):467-471. PubMed ID: 37689526 [No Abstract] [Full Text] [Related]
10. How should we use convalescent plasma therapies for the management of COVID-19? Wood EM; Estcourt LJ; McQuilten ZK Blood; 2021 Mar; 137(12):1573-1581. PubMed ID: 33202419 [TBL] [Abstract][Full Text] [Related]
11. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Pang NY; Pang AS; Chow VT; Wang DY Mil Med Res; 2021 Aug; 8(1):47. PubMed ID: 34465396 [TBL] [Abstract][Full Text] [Related]
12. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres. Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868 [TBL] [Abstract][Full Text] [Related]
13. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Diorio C; Anderson EM; McNerney KO; Goodwin EC; Chase JC; Bolton MJ; Arevalo CP; Weirick ME; Gouma S; Vella LA; Henrickson SE; Chiotos K; Fitzgerald JC; Kilbaugh TJ; John ARO; Blatz AM; Lambert MP; Sullivan KE; Tartaglione MR; Zambrano D; Martin M; Lee JH; Young P; Friedman D; Sesok-Pizzini DA; Hensley SE; Behrens EM; Bassiri H; Teachey DT Pediatr Blood Cancer; 2020 Nov; 67(11):e28693. PubMed ID: 32885904 [TBL] [Abstract][Full Text] [Related]
14. Kinetics of anti-SARS-COV2 spike protein IgG and IgA antibodies at 4°C: Implications for convalescent plasma stability. Focosi D; Moscato G; Pistello M; Maggi F Transfus Med; 2021 Jun; 31(3):221-222. PubMed ID: 33899263 [No Abstract] [Full Text] [Related]
15. Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors. Franchini M; Glingani C; Liumbruno GM; Mengoli C Transfus Apher Sci; 2021 Dec; 60(6):103216. PubMed ID: 34315677 [No Abstract] [Full Text] [Related]
16. Rethinking the role of COVID-19 convalescent plasma in the critically ill. Casadevall A; Pirofski LA Transfus Apher Sci; 2023 Feb; 62(1):103521. PubMed ID: 35941021 [No Abstract] [Full Text] [Related]
18. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428 [TBL] [Abstract][Full Text] [Related]
19. On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy. Focosi D; Franchini M; Casadevall A Viruses; 2022 Oct; 14(11):. PubMed ID: 36366476 [TBL] [Abstract][Full Text] [Related]
20. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma. Razumikhin M; Smolyanova T; Nikolaeva A; Orlova E; Ivanov A; Belyakova O; Vyaznikova T; Selezneva N; Perevozchikov A; Sokolova A; Zubkova N; Efimova I; Dolzhikova I; Logunov D; Sakanjan E Immunotherapy; 2022 Oct; 14(14):1133-1147. PubMed ID: 35892311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]